Edwards Lifesciences Outlines Vision For Growth At Investor Conference
Edwards Lifesciences Shares Are Trading Higher After Company Provided an Updated FY25 Guidance.
Edwards Lifesciences Expects 2025 Sales Of $5.6B-$6B Vs. Consensus Of $5.91B, With Adjusted EPS Of $2.40-$2.50 Versus Consensus Of $2.44, Reaffirms 2024 Constant Currency Sales Growth Guidance Of 8%-10%
(BSX) - Analyzing Boston Scientific's Short Interest
Price Over Earnings Overview: Medtronic
Stocks With Improving and Deteriorating 'TechniGrade' by Piper Sandler
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
A Glimpse Into The Expert Outlook On IDEXX Laboratories Through 5 Analysts
Cracking The Code: Understanding Analyst Reviews For Stryker
This Gap Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Stryker Analyst Ratings
IDEXX Laboratories Analyst Ratings
Peering Into GE HealthCare Techs's Recent Short Interest
10 Health Care Stocks With Whale Alerts In Today's Session
Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings
Becton, Dickinson and Company 10-K Risk Factors Highlight Intensified Global Economic Pressures, Stricter Regulations, Evolving Cybersecurity Threats, Climate Change Impacts, Geopolitical Risks, And Expanded Focus On Competition, Healthcare Costs, And...
The Analyst Verdict: Edwards Lifesciences In The Eyes Of 17 Experts
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
Edwards Lifesciences Analyst Ratings